NewLimit Raises $130 Million for Anti-Aging Research

Cryptos: 21,330
Exchanges: 1,863
Market Cap: $3.43T 1.37%
24h Vol: $261,024,107,496 25.72%
Dominance: BTC: 62.7% ETH: 9.2%
Gas: 1 GWEI

Connect

Crypto News AI

Brian Armstrong’s NewLimit Raises $130 Million for Anti-Aging Research

Written by Aaron S.,

Editor-In-Chief

Last Updated: May 07, 2025

Key Takeaways

NewLimit, co-founded by Coinbase’s Brian Armstrong, raised $130 million to develop therapies that extend healthy human lifespans;
The company uses AI and genomics through its Discovery Engine to study and adjust human cell behavior without altering DNA;
NewLimit believes that targeting aging through epigenetic reprogramming could help prevent many major diseases in the future.

Ace quick missions & earn crypto rewards while gaining real-world Web3 skills. Participate Now ! 🔥

Brian Armstrong’s NewLimit Raises $130 Million for Anti-Aging Research

BITDEGREE IN YOUR SOCIAL FEED

A biotech company co-founded by Coinbase $2.15B CEO Brian Armstrong, NewLimit, has secured $130 million in new funding.

The funding round, called Series B, was led by Kleiner Perkins, according to a May 6 statement.

New investors joining in this round include former GitHub CEO Nat Friedman, Daniel Gross, who used to lead machine learning efforts at Apple, and Khosla Ventures.

What is FUD in Crypto? (Fear, Uncertainty & Doubt Explained)

Did you know?

Want to get smarter & wealthier with crypto?

Subscribe - We publish new crypto explainer videos every week!

Armstrong started NewLimit with Blake Byers, a former GV partner, and stem cell researcher Jacob Kimmel. The company is working on therapies that aim to extend the number of healthy years a person can live. The approach focuses on changing how cells work by adjusting the epigenome, which affects cell behavior without altering the DNA.

NewLimit believes that aging is not just a natural process but a key factor behind many major diseases. The company explained that while aging was once thought to be permanent, new research in epigenetic reprogramming suggests it can be changed.

The company uses a combination of genomics and artificial intelligence (AI). Its main tool, called the Discovery Engine, tests thousands of ways to adjust human cells and studies the results. Machine learning models then help decide which changes to test next.

In a statement, NewLimit stated, "Our bet is that this combination of AI and scaled genomics can unlock medicines that give each of us more healthy years".

Recently, Neuralink, the brain tech company founded by Elon Musk, invited people to participate in its global brain chip trials. What is the aim of the trial? Read the full story.